Compare Adaptive Biotechnologies Corp (ADPT) vs Etsy Inc (ETSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Etsy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Etsy Inc trades at $76.54 (market cap $7.36B). The key difference: Etsy Inc is far larger — about 2.2× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | ETSY | |
|---|---|---|
Market Cap | $3.33B | $7.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $79.66 |
52-Week Low | $10.24 | $44.05 |
Enterprise Value | $3.19B | $9.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ETSY trades at $77.59, up 0.81% today, with a bullish technical signal from moving averages and support at $74. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.89 beating expectations of $0.62 (Seeking Alpha, 2026-05-29). Revenue for 2025 was $2.88B, though net income declined to $163M. Analyst consensus is a Buy with a $70.79 price target, and recent news highlights growth in AI seller tools and buyer recovery momentum.
ETSY shows potential with strong profitability margins and positive cash flow trends, but faces risks from high debt and competitive pressures. The stock's valuation multiples like P/E of 28.76 suggest moderate premium, while institutional sentiment remains cautiously optimistic amid execution challenges in sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
